FORM PTO-1449 (REV.7-80)			S. DEPARTMENT (TENT AND TRAD		ATTY, DOCKET NO. 110186.53659C23		APPLICATION NO. 10/775,897			
O INFORMATION DISCLOSURE STATEMENT					APPLICANTS Donald B. Axworthy et al.					
JUL 3 0 2004 💆		(Use several sheets if necessary)			FILING DATE February 10, 2004 GROUP ART UNIT 4642 GROUP ART UNIT 4642 GROUP ART UNIT			4		
U.S. PATENT DOCUMENTS										
INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS SUBCLASS		DATE OPRIATE	
ous	AA	4,639,365	01/27/87	Sherry		424	9.363			
	AB	4,647,447	03/03/87	Gries et al	•	424	9.36			
	AC	4,833,251	05/23/89	Musso et a	al.	548	304.1			
	AD	4,863,713	09/05/89	Goodwin	et al.	424	1.1			
	ΑE	4,895,955	01/23/90	Ford et al.		548	304.1			
	AF	4,898,951	02/06/90	Symons		548	304.1			
	AG	5,141,966	08/25/92	Porath		521	32			
:	АН	5,256,395	10/26/93	Barbet et a	al.	424	1.57			
	Αl	5,326,778	07/05/94	Rosebrough			387			
V.C	AJ	5,482,698	01/09/96	Griffiths		424	1.41			
			FOREI	GN PATEN	T DOCUMENTS					
		DOCUMENT NUMBER	DATE	- COUNTRY				YES	NO NO	
Dus	AK	EP 251 494	01/07/88	EPO			,			
	AL	EP 327 365	08/09/89	EPO						
	AM	EP 451 824	10/16/91	EPO	,					
	AN 1	EP 496 074	07/29/92	ЕРО						
V	AO	WO 88/08422	11/03/88	WIPO	· .					
		отне	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)		,	
DW	Axworthy et al., "Antibody Pretargeting For Radioimmunotherapy: A Three-Step Approach In Tumored Nude Mice," <i>The Journal Of Nuclear Medicine; Proceedings Of The 39th Annual Meeting 33</i> : p. 880, Abstract No. 234, 1992.									
	ΑQ	Chatteriee, Cancer Immunol, Immunother, 38: 75-82, 1994.								
V.	AR	Curti, Crit. Rev. Oncol./Hematol. 14: 29, 1993.								
EXAMINE		aSau	dus		DATE CONSIDERED	i1/	9/04			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).										

FORM PTO-1449 U.S. DEPARTMENT OF COMPARED TO TRADEMARN				ATTY, DOCKET NO. APPLICATION NO. 110186.53659C23 10/775,897						
INICODALATION DICCI OCUDE CTATEMENT					APPLICANTS					
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					Donald B. Axworthy et al.				 -	
, , , , , , , , , , , , , , , , , , , ,					Filing date Group art unit February 10, 2004 1642					
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER	OCCUMENT NUMBER DATE NAME CLASS SUBCL				SUBCLASS	FILING DATE IF APPROPRIATE		
sul	B _A -	-5,525,338	06/11/96	Goldenberg 424 1781						
6	ВB	5,690,907	11/25/97	Lanza			424 9.5			
2	вс	5,736,119	04/07/98	Goldenberg et al.			424 1.53			
V	BD	6,120,768	09/19/00	Griffiths e	t al.	424 178.1		178.1		
	BE		,							
	BF									
	BG									
	ВН								-	
	ВІ		<u></u>							
	ву								-	
			FOREI	GN PATEN	T DOCUMENTS					
n		DOCUMENT NUMBER	DATE	COUNTRY				TRANSI YES	ATION NO	
DW.	BK	WO 89/10140	11/02/89	WIPO						
\ :	BL	WO 90/12050	10/18/90	WIPO	WIPO					
	ВМ	WO 92/12730	08/06/92	WIPO	110					
	BN	WO 93/15210	08/05/93	WIPO		<u>-</u>				
V	во	WO 94/17829	08/18/94	WIPO						
		ОТНЕ	ER PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)			
01	Galli et al., "A Radiopharmaceutical For The Study Of The Liver: 99m Tc-DTPA-A									
SW	OROSOMUCOID. II: Human Dynamic and Imaging Studies," The Journal Of N Medicine And Allied Sciences 32: 117-126, 1988.							Nucieo	ır	
	BQ				Clinicians, 44:43, 199	4.			_	
1/	BR	Goodwin et al., "Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-						in-		
EXAMINE	ER	1 - 0		ny," J. Nuci	l. Med.: p. 880, Abstra DATE CONSIDERED	ict No	232 المس	., 1992.		
Dand a Saunders 11/15/04										
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).										

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE				ATTY, DOCKET NO. 110186.53659C23		APPLICATION NO. 10/775,897					
INFORMATION DISCLOSURE STATEMENT					APPLICANTS Donald B. Axworthy et al.						
		(Use several sheets if no	ecessary)		FILING DATE GROUP ART UNIT February 10, 2004 1642						
			U.S	. PATENT I	DOCUMENTS						
*EXAMINER INITIAL					NAME	CLASS	FILING DATE IF APPROPRIATE				
	CA										
	СВ										
			FORE	GN PATEN	T DOCUMENTS						
		DOCUMENT NUMBER	DATE		COUNTRY	TRANSLATION YES NO					
	сс										
	l	ОТИ	ED DDIAD A	PT (In aboding	Author Title Data Partiant Pa	Fra.)					
Oul	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Goodwin, "New Methods for Localizing Infection: A role for Avidin-Biotin,?" J. Nucl.										
	CD	Med. 33(10):	1816-1818,	1992.							
	CE	Goodwin/Hn	Goodwin/Hnatowich, Letter to the Editor/Reply, J. Nucl. Med. 32(4): 750-751, 1991.								
,	CF	Green, "The 1963.	Green, "The Use of [14C]Biotin for Kinetic Studies and for Assay," <i>Biochem. J.</i> 89: 585, 1963.								
e.	CG	Harris et al.,	Harris et al., Tibtech 11: 42, 1993.								
	СН		Hnatowich et al., "Investigations of Avidin and Biotin for Imaging Applications," J. Nucl. Med. 28(8): 1294-1302, 1987.								
	CI		Jain, Scientific American 271(1): 58, 1994.								
	င္ပ		Jokiranta et al., "Biotinylation of Monoclonal Antibodies Prevents Their Ability to Activate the Classical Pathway of Complement," The Journal of Immunology 151(4): 1'14- 2131 1993								
ι.	СК	Kalofonos et Streptavidin	Kalofonos et al., "Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication," J. Nucl. Med. 31(11): 1791-1796, 1990.								
1	CL	i 1	Koch and Macke, "99m-Tc Labeled biotin conjugates in a Tumor "Pretargeting" Approach with Monoclonal Antibodies," Angew. Chem. Intl. Ed. Engl. 31(11): 1507-1509, 1992.								
	СМ	Kricka et al.	Kricka et al., "Survey of Methods of Measuring Human Anti-Mouse Antibodies," HAMA Survey Group, Clinica Chimica Acta. 215: 153-163, 1993.								
	CN	McMurry et	McMurry et al., "Covenient Synthesis of Bifunctional Tetraaza Macrocycles," Bioconjugate Chem. 3(2): 108-117, 1992.								
V	со		Osband et al., Immunol. Today 11: 193, 1990.								
EXAMINI	ER C	Faire a.	Janes	'es_	DATE CONSIDERED	11/1	5/04				
* EXAMIN	ER:		-		nformance with MPEP 609. Draw	-	citation if not in				

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. APPLICATION NO. 110186.53659C23 10/775,897								
INFO	DRM.	ATION DISCLOSU	RE STATEM	ENT	APPLICANTS Donald B. Axworthy	et al.					
(Use several sheets if necessary)				FILING DATE GROUP ART UNIT February 10, 2004 1642							
			U.S.	PATENT I	DOCUMENTS						
*EXAMINER DOCUMENT NUMBER DATE			NAME	CLASS			NG DATE PROPRIATE				
	DA										
			FOREI	GN PATEN	T DOCUMENTS	-					
489.1		DOCUMENT NUMBER	DATE	COUNTRY	-		TRANSLATION YES NO				
	DB				YE						
	L., .,	OTHE	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pag	nes Fic)					
Oct					io-Localization of Tun		Targeted by	,			
on M	DC	Biotinylated	Monoclonal	Antibodies	s," Int. J. Cancer 45: 11	184-1189	, 1990.				
1	DD		Paganelli et al., "Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system," <i>Nuclear Medicine Communications</i> 12: 211-234, 1991.								
	Renn and Meares, "Large-Scale Synthesis of Bifunctional Chelating Agent 2-(p-Nitrobenzyl)-								-		
	1.72		1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic Acid, and the Determination of Its Enantiomeric Purity by Chiral Chromatography," <i>Bioconjugate Chem.</i> 3(6): 563-569, 1992.								
	DF	Rosario et al	Rosario et al., "Bolton-Hunter and Biotin Derivatized Polylysine: A New Multi-Valent								
			Peptide Reagent for <i>In Vivo</i> Pre-Targeting with Streptavidin Conjugates," <i>J. Nucl. Med.</i> 32(5): p. 993, Abstract No. 356, 1991.								
	DG		Rosebrough, "Plasma Stability and Pharmacokinetics of Radio-labeled Deferoxamine-								
	00		Biotin derivatives," J. Nucl. Med.: p. 880, Abstract No. 235, 1992.								
12	DH		Sanderson et al., "Preparation And Characterization Of Biotin conjugates Of Anti-Pan-Carcinoma NR-LU-10 Monoclonal Antibody For A Three Step radioimmunotherapy," <i>The Journal Of</i>								
			Nuclear Medicine; Proceedings Of The 39th Annual Meeting 33: p. 880, Abstract No. 233, 1992. Van der Sluijs et al., "Drug Targeting to the Liver with Lactosylated Albumins: Does the								
	DI				ig to the Liver with Lac he Drug Targeting the						
- Z		723-728, 198	36.								
	נס	· · · · ·	Virzi et al., "New Indium-111 Labeled Biotin Derivatives for Improved Immunotargeting," Nucl. Med. Biol. 18(7): 719-726, 1991.								
					valuation of 12 Biotin I	Derivativ	es labeled w	ith Tc	-		
	DK	99M," <i>J. Nuc</i>	99M," J. Nucl. Med.: p. 920, Abstract No. 403, 1992.								
	DL		Wolf et al., Methy. Enzym. 184: 103, 1990.								
\	DМ				ed Macrocycles for IIII			of Prot	eins,"		
	Nucl. Med. Biol. Int. J. Radiat. Appl. Instrum. Part B 19(2): 239-244, 1992. Zwierzina, StemCells 11: 144, 1993.										
EXAMINE	DN C	called (1)	aund		DATE CONSIDERED						
* EVAND		DOVA UX			forward with MARTH (00 Power	11/15/	04				
* EXAMIN					nformance with MPEP 609. Draw		Citation II not in				